Clinical trial
Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or…
NCT00425191 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00425191 |
|---|---|
| Title | Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer. |
| Official title | A Multicenter, Randomized Phase II Study Evaluating the Feasibility and Activity of Two Different Combinations of Docetaxel and Gemcitabine and of Cisplatin/Gemcitabine Followed by Docetaxel as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer. |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel and Gemcitabine, Gemcitabine cisplatin followed by docetaxel |
| Enrollment | 165 |
| Start date | Jul 1, 2002 |
| Primary completion | Apr 1, 2005 |
| First posted | Jan 22, 2007 |
| Last update posted | Dec 7, 2009 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: